NEW YORK (GenomeWeb News) – Compugen today reported a 23 percent increase in its fourth-quarter loss and "insignificant" revenues of $11,000 for the three-month period ended Dec. 31.

The Tel Aviv, Israel-based computational biology firm said that its revenues declined from $90,000 for the fourth quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.